帕金森症（PD）是一种渐进性的神经系统退行性疾病。现有的药物虽对帕金森症的运动症状有效，但大多数药物都有一定的不良反应，且对非运动症状和神经退化的改善还远未得到满足。在前期抗精神分裂症药物研究中，我们发现部分化合物具有 D2/D3/5-HT1A多重激动活性。受此鼓舞，本课题采用计算机辅助的药物设计，设计合成具有D3/D2/5-HT1A多靶点作用的抗帕金森症新化合物以期获得具有高体内外活性、良好药代动力学性质的抗帕金森症候选药物，同时研究该系列化合物对帕金森症情绪障碍共病的影响，研究D3/5-HT1A激动活性对帕金森症认知功能损伤的改善，研究该系列化合物的神经保护作用。

Pathological findings have revealed that Parkinson’s disease is a neurodegenerative disorder. Although currently available drugs are generally effective, they can cause serious side-effects. Additionally, there are still unmet clinical needs such as non-motor symptoms. In our previous study to find novel antipsychotic drugs, we found that some compounds have multi-target effect as D2/D3/5-HT1A receptor agonist. Encouraged by this result, we plan to find novel potential anti-parkinsonian molecular which have high-potency and suitable pharmacokinetic properties. Our study includes: 1. Design and synthesis of novel compounds with D3/D2/5-HT1A multi-target effect as anti-parkinsonian agents utilizing computer aided drug design technique; 2. Study effects of D3/D2/5-HT1A agonists on mood disorders in PD; 3. Study the D3/5-HT1A agonism effect of these compounds on regulating cognitive dysfunction in PD; 4. Study the neuroprotection effect of these D3/D2/5-HT1A agonists.